SYRS Syros Pharmaceuticals, Inc.
Healthcare$0.00-50.00%ClosedMarket Cap: $5,366
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
0.49
DCF Value
$-8.70
FCF Yield
-1024680.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.3%
Operating Margin
-1298.2%
Net Margin
-1656.3%
ROE
-227.9%
ROA
-97.9%
ROIC
-91.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $0.00 | -Infinity% | $-26.2M | $-6.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-27.4M | $-23.3M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-30.9M | $-3.7M | $— | — |
| Q4 null | $386.0K | 27.7% | $-27.0M | $-64.4M | $— | — |
| FY null | $9.9M | 77.3% | $-129.0M | $-164.6M | $— | — |
| Q3 null | $3.8M | 83.6% | $-34.6M | $-40.1M | $— | — |
| Q2 null | $2.8M | 77.0% | $-34.0M | $-36.3M | $— | — |
| Q1 null | $3.0M | 76.2% | $-33.2M | $-14.9M | $— | — |
| Q4 null | $-5.5M | 114.1% | $-36.0M | $27.6M | $— | — |
| FY null | $14.9M | 80.1% | $-135.9M | $-94.7M | $— | — |
| Q3 2022 | $3.9M | 81.4% | $-39.5M | $-21.1M | $-2.24 | — |
| Q2 2022 | $6.3M | 88.4% | $-33.8M | $-35.2M | $-5.51 | — |